Natálie Klubíčková
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natálie Klubíčková has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
- Josephine Kamtai Dermawan
Department of Pathology and Laboratory Medicine Cleveland Clinic Cleveland Ohio USA
12 shared publications - Michael Michal
Department of Pathology, Faculty of Medicine in Plzen, Charles University, Prague, Czech Republic
12 shared publications - Petr Martínek
Šikl’s Department of Pathology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
11 shared publications - John M. Gross
Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10 shared publications - Boulos Mansour
Department of Pathology, Ospedale Israelitico, Rome, Italy.
9 shared publications - Carina A. Dehner
Department of Pathology and Laboratory Medicine Hospital of the University of Pennsylvania Philadelphia PA USA
9 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by Elsevier in Laboratory Investigation
- Vol. 39 (8) , 101025
Clinicopathological, Molecular, and DNA Methylation Analysis of Ossifying Fibromyxoid Tumors Delineates the ZC3H7B::BCOR Subset as a Distinct Entity
- 16 June 2026
- Published by Elsevier in Laboratory Investigation
- Vol. 39 (8) , 101025
Open AccessClinicopathological, Molecular, and DNA Methylation Analysis of Ossifying Fibromyxoid Tumors Delineates the ZC3H7B::BCOR Subset as a Distinct Entity
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Data from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Purpose:Fusion-positive myoepithelial tumors (MET) are clinicopathologically heterogeneous and variably termed mixed tumors and myoepithelial carcinomas. As FET-rearranged METs lack ductal/epithelial differentiation, we test whether FET-rearranged METs are epigenetically distinct from adnexal PLAG1-rearranged METs, which we hypothesize to be analogues of salivary gland METs.Experimental Design:DNA methylation profiling from a multi-institutional cohort of 52 fusion-positive skin, soft-tissue, and bone MET cases was performed and compared with diverse tumor types, including salivary METs. The MET subgroups harbored EWSR1::KLF15, EWSR1/FUS::KLF17, EWSR1::PBX1, EWSR1::PBX3, EWSR1/FUS::POU5F1, SS18::POU5F1, EWSR1::ZNF444, and PLAG1 rearrangements. Pooled clinicopathologic and outcome analysis with new and published cases (total 185) was performed.Results:The MET subgroups showed significant heterogeneity in age, site, and histology. Specifically, EWSR1::KLF15 METs affected predominantly young children (<5 years); EWSR1::PBX1/PBX3 METs were enriched in skin/bone; and EWSR1/FUS::POU5F1, SS18::POU5F1, and EWSR1::KLF15 METs tended to display malignant histology. Conversely, PLAG1-rearranged tumors were predominantly benign, arising in older adults and located in the skin. DNA methylation profiling revealed that FET-rearranged METs were epigenetically related to SS18::POU5F1 METs and FET::NFATC2 sarcomas but entirely distinct from PLAG1-rearranged adnexal and salivary METs. Histologic features were correlated with the degree of genome-wide copy-number variation. The median disease-specific survival was shortest in SS18::POU5F1 (31 months), EWSR1::PBX3 (38 months), and EWSR1::KLF15 (45 months) METs. On multivariate analysis, age <25 years was a significant predictor of worse progression-free survival.Conclusions:FET-rearranged METs are epigenetically unrelated to cutaneous and salivary gland METs, and their malignant counterparts are best classified as sarcomas rather than carcinomas.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Purpose:Fusion-positive myoepithelial tumors (MET) are clinicopathologically heterogeneous and variably termed mixed tumors and myoepithelial carcinomas. As FET-rearranged METs lack ductal/epithelial differentiation, we test whether FET-rearranged METs are epigenetically distinct from adnexal PLAG1-rearranged METs, which we hypothesize to be analogues of salivary gland METs.Experimental Design:DNA methylation profiling from a multi-institutional cohort of 52 fusion-positive skin, soft-tissue, and bone MET cases was performed and compared with diverse tumor types, including salivary METs. The MET subgroups harbored EWSR1::KLF15, EWSR1/FUS::KLF17, EWSR1::PBX1, EWSR1::PBX3, EWSR1/FUS::POU5F1, SS18::POU5F1, EWSR1::ZNF444, and PLAG1 rearrangements. Pooled clinicopathologic and outcome analysis with new and published cases (total 185) was performed.Results:The MET subgroups showed significant heterogeneity in age, site, and histology. Specifically, EWSR1::KLF15 METs affected predominantly young children (<5 years); EWSR1::PBX1/PBX3 METs were enriched in skin/bone; and EWSR1/FUS::POU5F1, SS18::POU5F1, and EWSR1::KLF15 METs tended to display malignant histology. Conversely, PLAG1-rearranged tumors were predominantly benign, arising in older adults and located in the skin. DNA methylation profiling revealed that FET-rearranged METs were epigenetically related to SS18::POU5F1 METs and FET::NFATC2 sarcomas but entirely distinct from PLAG1-rearranged adnexal and salivary METs. Histologic features were correlated with the degree of genome-wide copy-number variation. The median disease-specific survival was shortest in SS18::POU5F1 (31 months), EWSR1::PBX3 (38 months), and EWSR1::KLF15 (45 months) METs. On multivariate analysis, age <25 years was a significant predictor of worse progression-free survival.Conclusions:FET-rearranged METs are epigenetically unrelated to cutaneous and salivary gland METs, and their malignant counterparts are best classified as sarcomas rather than carcinomas.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S2. Unsupervised hierarchical clustering heatmap of DNA methylation beta values (top 5000 by variance) across selected tumor types. Shown are the genes corresponding to the top 100 cpg sites.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S2. Unsupervised hierarchical clustering heatmap of DNA methylation beta values (top 5000 by variance) across selected tumor types. Shown are the genes corresponding to the top 100 cpg sites.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S10 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Table S1. Clinicopathologic features of new and published cases of EWSR1/FUS::POU5F1-rearranged MET Suppl. Table S2. Clinicopathologic features of new and published cases of SS18::PBX1/3-rearranged MET Suppl. Table S3. Clinicopathologic features of new and published cases of EWSR1::KLF15-rearranged MET Suppl. Table S4. Clinicopathologic features of new and published cases of EWSR1/FUS::KLF17-rearranged MET Suppl. Table S5. Clinicopathologic features of new and published cases of EWSR1::ZNF444-rearranged MET Suppl. Table S6. Clinicopathologic features of new and published cases of EWSR1::PBX1/3-rearranged MET Suppl. Table S7. Clinicopathologic features of new and published cases of PLAG1-altered MET Suppl. Table S8. Clinicopathologic summary of fusion-positive myoepithelial tumors (new and published cases) Suppl. Table S9. Significant differentially methylated regions: ENT and cutaneous PLAG1-rearranged vs FET-rearranged myoepithelial tumors Suppl. Table S10. Univariate and Multivariate Survival Analysis for Disease-specific Survival (DSS) and Progression-free Survival (PFS)
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S10 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Table S1. Clinicopathologic features of new and published cases of EWSR1/FUS::POU5F1-rearranged MET Suppl. Table S2. Clinicopathologic features of new and published cases of SS18::PBX1/3-rearranged MET Suppl. Table S3. Clinicopathologic features of new and published cases of EWSR1::KLF15-rearranged MET Suppl. Table S4. Clinicopathologic features of new and published cases of EWSR1/FUS::KLF17-rearranged MET Suppl. Table S5. Clinicopathologic features of new and published cases of EWSR1::ZNF444-rearranged MET Suppl. Table S6. Clinicopathologic features of new and published cases of EWSR1::PBX1/3-rearranged MET Suppl. Table S7. Clinicopathologic features of new and published cases of PLAG1-altered MET Suppl. Table S8. Clinicopathologic summary of fusion-positive myoepithelial tumors (new and published cases) Suppl. Table S9. Significant differentially methylated regions: ENT and cutaneous PLAG1-rearranged vs FET-rearranged myoepithelial tumors Suppl. Table S10. Univariate and Multivariate Survival Analysis for Disease-specific Survival (DSS) and Progression-free Survival (PFS)
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S5. Kaplan–Meier curves illustrating disease-specific survival (DSS) stratified by age group (A) and tumor size (B). Forest plots illustrating multivariate Cox-regression analysis of progression-free survival (C).
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S5. Kaplan–Meier curves illustrating disease-specific survival (DSS) stratified by age group (A) and tumor size (B). Forest plots illustrating multivariate Cox-regression analysis of progression-free survival (C).
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S6. Kaplan–Meier curves illustrating progression-free survival (PFS) stratified by age group (A) and tumor size (B). Forest plots illustrating multivariate Cox-regression analysis of progression-free survival (C).
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S6. Kaplan–Meier curves illustrating progression-free survival (PFS) stratified by age group (A) and tumor size (B). Forest plots illustrating multivariate Cox-regression analysis of progression-free survival (C).
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S4. Differentially methylated regions M values between salivary/PLAG1-rearranged vs FET-rearranged myoepithelial tumors.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S4. Differentially methylated regions M values between salivary/PLAG1-rearranged vs FET-rearranged myoepithelial tumors.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S3. Unsupervised hierarchical clustering of DNA methylation beta values (top 1000 by variance) across FET-rearranged myoepithelial tumors and NFATC2 -rearranged sarcoma. Shown are the genes corresponding to top 200 cpg sites by variance.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S3. Unsupervised hierarchical clustering of DNA methylation beta values (top 1000 by variance) across FET-rearranged myoepithelial tumors and NFATC2 -rearranged sarcoma. Shown are the genes corresponding to top 200 cpg sites by variance.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S1. Scree plot (A). PCA plot before (B) and after (C) dimensionality reduction by UMAP.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S1. Scree plot (A). PCA plot before (B) and after (C) dimensionality reduction by UMAP.
- Open Access
- 1 January 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- p. 1-11
A Multicentric Dataset for Training and Benchmarking Breast Cancer Segmentation in H&e Slides
- 1 January 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- p. 1-11
Open AccessA Multicentric Dataset for Training and Benchmarking Breast Cancer Segmentation in H&e Slides